Focus Partners Wealth
PTGX icon

Focus Partners Wealth’s Protagonist Therapeutics PTGX Stock Holding History

Focus Partners Wealth’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
+11,878
New +$1.24M ﹤0.01% 1479
2025
Q4 		– Sell
-448,988
Closed -$29.8M – 2770
2025
Q3 		$29.8M Buy
+448,988
New +$25.5M 0.05% 309
2025
Q2 		– Sell
-435,097
Closed -$21M – 2115
2025
Q1 		$21M Buy
435,097
+9,540
+2% +$400K 0.05% 319
2024
Q4 		$16.4M Sell
425,557
-1,104
-0.3% -$48.1K 0.04% 356
2024
Q3 		$19.2M Buy
+426,661
New +$17.2M 0.06% 289

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Focus Partners Wealth's PTGX Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 11,878 shares worth $1.46M. The stake represents ﹤0.01% of the portfolio and ranks #1479 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in PTGX as recently as Q3 2025.

Focus Partners Wealth first reported a position in PTGX in Q3 2024 and has held it in 5 quarters since. The position peaked at $29.8M in Q3 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Focus Partners Wealth held 11,878 shares of Protagonist Therapeutics worth $1.46M as of Q2 2026.
  • Protagonist Therapeutics was a new Focus Partners Wealth position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1479 holding.
  • Focus Partners Wealth first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Focus Partners Wealth's Protagonist Therapeutics position peaked at $29.8M in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.